healthbook News from the EHA® 2018

healthbook’s Independent Conference Highlights*

Expert Interviews

Video published with permission from
Dr Davide Rossi
New Treatment Options in CLL
Personal Highlights from Dr Davide Rossi
Dr Davide Rossi shared his personal highlights from the EHA 2018 on practice-changing treatment options for patients with chronic lymphocytic leukemia (CLL).Watch the video interview here >>>

Video published with permission from
Dr Alexandre Theocharides
Myeloproliferative Neoplasms
Personal Highlights from Dr Alexandre Theocharides
Dr Alexandre Theocharides talked about his personal highlights from the EHA 2018 with regard to myeloproliferative neoplasms (MPNs).Watch the video interview here >>>

Video published with permission from
Prof. Dr Christoph Renner
CLL and FL
Interview with Prof. Dr Christoph Renner
In this video interview, Prof. Dr Christoph Renner discusses the use of the anti-CD20 antibody obinutuzumab in chronic lymphocytic leukemia (CLL) and in follicular lymphoma (FL), focusing on the CLL11 and GALLIUM trials, respectively.Watch the video interview here >>>

 

Study Highlights
Chronic Lymphocytic Leukemia
Early Results from the Phase II CAPTIVATE Study
The early results of the phase II CAPTIVATE study support the safety, activity, and tumor lysis syndrome (TLS) risk reduction potential of ibrutinib lead-in and show promising activity of ibrutinib + venetoclax oral regimen in treatment-naïve patients with chronic lymphocytic leukemia (CLL).
Read more

Reference: Ghia et al. Ibrutinib lead-in followed by venetoclax in patients with chronic lymphocytic leukema: phase 2 CAPTIVATE early safety and efficacy results. EHA Annual Congress. Abstract S806. Obtained from the EHA website http://www.ehaweb.org

 

Relapsed/Refractory Chronic Lymphocytic Leukemia
MRD Kinetics and Responses from the Phase III MURANO Study
In the phase III MURANO study, venetoclax + rituximab (VenR) for 6 months, followed by single-agent venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) resulted in high, early, deep and durable peripheral blood (PB) minimal residual disease negativity (MRD−; <1 CLL cell in 10,000 leukocytes [<10-4]) regardless of risk features, unlike bendamustine + rituximab (BR).
Read more

Reference: Hillmen et al. High, durable minimal residual disease (MRD) negativity with venetoclax + rituximab in relapsed/refractory CLL: MRD kinetics and responses in cytogenetic risk groups in pts from phase 3 MURANO study. EHA Annual Congress. Abstract S805. Obtained from the EHA website http://www.ehaweb.org

 

Chronic Lymphocytic Leukemia
Final Analysis of the Phase III CLL11 Study
The final overall survival (OS) analysis from the CLL11 trial confirms the clinically meaningful benefit observed with obinutuzumab plus chlorambucil compared with rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL) and comorbidities.
Read more

Reference: Goede et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: Final survival analysis of the CLL11 study. EHA Annual Congress. Abstract S151. Obtained from the EHA website http://www.ehaweb.org

 

Classical Hodgkin Lymphoma
Prespecified Sub-Group Analysis from the ECHELON-1 Study
A prespecified subgroup analysis from the ECHELON-1 phase III study showed that patients with classical Hodgkin lymphoma (cHL) and high-risk features may benefit from frontline treatment with A+AVD as opposed to treatment with ABVD.
Read more

Reference: Hutchings et al. Brentuximab vedotin plus chemotherapy in high risk advanced-stage classical Hodgkin lymphoma (CHL) patients: Results of pre-specified sub-group analyses from the ECHELON-1 study. EHA Annual Congress. Abstract S112. Obtained from the EHA website http://www.ehaweb.org

 

Follicular Lymphoma
RELEVANCE Phase III Study
The phase III RELEVANCE study showed a favorable safety profile with similar efficacy outcomes for rituximab plus lenalidomide followed by rituximab maintenance (R2) compared with rituximab plus chemotherapy followed by rituximab maintenance (R-Chemo) in patients with previously untreated follicular lymphoma (FL).
Read more

Reference: Morschhauser et al. RELEVANCE: Phase III efficacy and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma. EHA Annual Congress. Abstract S154. Obtained from the EHA website http://www.ehaweb.org

 

Relapsed/Refractory Multiple Myeloma
Phase II ELOQUENT-3 Trial

The phase II ELOQUENT-3 trial of relapsed or refractory multiple myeloma (RRMM) showed significant improvement in progression-free survival (PFS) with elotuzumab plus pomalidomide/dexamethasone (EPd) versus pomalidomide plus dexamethasone (Pd).
Read more

Reference: Dimopoulos et al. Elotuzumab plus pomalidomide/Dexamethasone (EPd) vs Pd for treatment of relapsed/refractory multiple myeloma (RRMM): Results from the phase 2, randomized open-label ELOQUENT-3 study. EHA Annual Congress. Abstract LB2606. Obtained from the EHA website http://www.ehaweb.org

 

Chronic Lymphocytic Leukemia
Preliminary Results of the Phase II ICLL07 FILO Trial
The preliminary results of the phase II ICLL07 FILO trial suggest that the combination of obinutuzumab and ibrutinib in the first-line setting (a “chemo-free” induction regimen) of patients with chronic lymphocytic leukemia (CLL) results in a high complete response (CR) rate at 9 months without excess of toxicity.
Read more

Reference: Michallet et al. High rate of complete response but minimal residual disease still detectable after first-line treatment combining obinutuzumab and ibrutinib in chronic lymphocytic leukemia (CLL): ICLL07 FILO trial. EHA Annual Congress. Abstract S804. Obtained from the EHA website http://www.ehaweb.org

 

Relapsed/Refractory Multiple Myeloma
OPTIMISMM Phase III Trial
In the OPTIMISMM phase III trial, lenalidomide (len)-exposed patients with relapsed/refractory multiple myeloma (r/r MM) showed a significant improvement in progression-free survival (PFS) when treated with pomalidomide, bortezomib and low-dose dexamethasone (PVd) compared with bortezomib plus low-dose dexamethasone (Vd).
Read more

Reference: Richardson et al. OPTIMISMM: Phase 3 trial of pomalidomide, bortezomib, and low-dose dexamethasone vs bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed/refractory multiple myeloma. EHA Annual Congress. Abstract S847. Obtained from the EHA website http://www.ehaweb.org